Novartis AG v. Union of India ((2013) 6 SCC 1) established that Section 3(d) of the Patents Act, 1970, requires any new form of a known pharmaceutical substance to demonstrate "significantly enhanced therapeutic efficacy" to be patentable, and that "efficacy" in this context means therapeutic efficacy — the ability to produce the desired therapeutic effect in patients — not improved physical properties. This interpretation directly governs pharmaceutical patent prosecution, pre-grant opposition, post-grant challenge, and generic drug defence strategies in 2026. Practitioners on both sides of pharmaceutical patent disputes — innovator companies seeking protection and generic manufacturers challenging patents — must structure their evidence and arguments around the therapeutic efficacy threshold articulated in this judgment.
Case overview
| Field | Details |
|---|---|
| Case name | Novartis AG v. Union of India |
| Citation | (2013) 6 SCC 1 |
| Court | Supreme Court of India |
| Bench | Aftab Alam, Ranjana Prakash Desai JJ. |
| Date of judgment | 1 April 2013 |
| Ratio decidendi | Section 3(d) requires significantly enhanced therapeutic efficacy for new forms of known substances; "efficacy" means therapeutic efficacy; improved physical properties alone are insufficient |
Material facts and procedural history
Novartis AG filed a patent application in India for the beta-crystalline form of imatinib mesylate, the active ingredient in Glivec (Gleevec), a revolutionary drug for chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). Imatinib in free base form was a known compound (originally patented by Ciba-Geigy, Novartis's predecessor, before India's product patent regime began in 2005). The Indian application, filed under the transitional "mailbox" provisions after India amended its Patents Act in 2005 to comply with TRIPS, claimed the beta-crystalline polymorph of imatinib mesylate as a new invention.
The application attracted pre-grant oppositions from generic pharmaceutical companies, cancer patient groups, and NGOs. The Chennai Patent Office rejected the application under Section 3(d), holding it was a new form of a known substance without enhanced efficacy. Novartis appealed to the Intellectual Property Appellate Board (IPAB), which upheld the Section 3(d) rejection while reversing other grounds. Novartis then filed a Special Leave Petition to the Supreme Court.
Before the Supreme Court, Novartis presented data showing improved bioavailability (30% increase), better thermodynamic stability, and superior flow properties of the beta-crystalline form. The patent applicant also challenged the constitutional validity of Section 3(d) as vague and argued it was TRIPS-incompatible.
Ratio decidendi
New form of known substance — The Court held that imatinib mesylate in its beta-crystalline form was a "new form of a known substance" within Section 3(d). Imatinib was the known substance. The beta-crystalline polymorph, being a different physical form of the same chemical entity, fell squarely within the Section 3(d) Explanation's list of new forms (which includes salts, esters, polymorphs, and other derivatives).
Therapeutic efficacy is the required standard — The Court held that "efficacy" in Section 3(d), when applied to pharmaceutical substances, means "therapeutic efficacy." This is the drug's ability to produce the intended therapeutic effect in the human body. The Court rejected Novartis's argument that improved physical properties (bioavailability, stability, processability) constitute "enhanced efficacy" under Section 3(d). While improved bioavailability might potentially lead to enhanced therapeutic efficacy, the applicant must demonstrate this through appropriate data.
Burden on the applicant — The applicant bears the burden of demonstrating significantly enhanced therapeutic efficacy. General assertions or theoretical possibilities are insufficient — the applicant must provide pharmacological, clinical, or equivalent scientific data showing that the new form produces a therapeutically superior outcome compared to the known substance.
Section 3(d) is constitutionally valid — The Court held that Section 3(d) is neither vague nor arbitrary. The standard of "enhanced efficacy" is sufficiently clear and can be applied by patent examiners and courts with the assistance of expert evidence. The provision serves the legitimate public interest of preventing evergreening while allowing genuinely innovative modifications to be patented.
Current statutory framework
Section 3(d) (unchanged since 2005 amendment): The provision and its Explanation remain as interpreted in Novartis. No legislative amendment has modified the "enhanced efficacy" standard. The Indian Patent Office's Manual of Patent Office Practice and Procedure incorporates the Novartis guidelines for examining pharmaceutical applications.
Section 2(1)(ja) — inventive step: Requires "technical advance" compared to existing knowledge or "economic significance" or both. In pharmaceutical cases, the inventive step analysis and the Section 3(d) analysis often overlap — a new form that fails Section 3(d) may also fail the inventive step requirement.
Section 84 — compulsory licensing: Available after 3 years from patent grant if the drug is not available at a reasonably affordable price, reasonable public requirements are not satisfied, or the invention is not worked in India. The first (and so far only) compulsory licence was granted in Bayer v. Natco Pharma (2012) for sorafenib tosylate.
Section 107A(b) — Bolar exception: Permits use of a patented invention for purposes reasonably related to development and submission of information for regulatory approval of a generic version. This allows generic manufacturers to prepare applications for regulatory approval before the patent expires.
Practice implications
For innovator company patent counsel: Section 3(d) fundamentally changes the patent prosecution strategy for pharmaceutical applications in India compared to the US or EU. When filing applications for new forms of known substances (salt forms, polymorphs, crystalline forms, prodrugs), prepare robust evidence of enhanced therapeutic efficacy before filing. This evidence should include: (a) comparative clinical trial data showing superior therapeutic outcomes (not just pharmacokinetic data), (b) if clinical data is unavailable, in vivo pharmacological studies demonstrating enhanced therapeutic effect, and (c) expert declarations linking improved bioavailability to enhanced therapeutic outcomes with supporting data. Applications relying solely on improved physical properties (stability, processability, dissolution) will be rejected.
Drafting specifications: In the patent specification, explicitly address Section 3(d) by: (a) clearly identifying the known substance and the new form, (b) presenting comparative efficacy data in the description, (c) drafting claims that emphasize the therapeutic innovation rather than merely the physical form, and (d) including a dedicated section explaining why the new form exhibits significantly enhanced therapeutic efficacy. Consider filing a composition or method-of-treatment claim rather than a product-per-se claim if the therapeutic advance lies in the administration rather than the compound itself.
For generic drug defence counsel: Section 3(d) is the most powerful tool available for pre-grant opposition, post-grant opposition, and revocation proceedings against pharmaceutical patents in India. When challenging a patent on a new form: (a) establish that the patented compound is a new form of a known substance (identify the prior art known substance), (b) argue that the patent holder has not demonstrated significantly enhanced therapeutic efficacy, (c) present expert evidence that improved bioavailability or physical properties do not automatically translate to enhanced therapeutic outcomes, and (d) invoke the Novartis Court's holding that the burden of proof lies on the patentee.
Pre-grant opposition strategy: File pre-grant oppositions under Section 25(1) citing Section 3(d) as soon as the patent application is published (18 months from filing). The earlier the opposition is filed, the more likely it will be considered before grant. Prepare a comprehensive opposition statement with: (a) identification of the known substance in prior art, (b) evidence that the claimed invention is a new form (salt, polymorph, derivative), and (c) analysis showing no significantly enhanced therapeutic efficacy has been demonstrated.
Post-grant challenge and revocation: For patents already granted, use Section 25(2) (post-grant opposition, within 1 year of grant) or Section 64 (revocation by IPAB or court) to challenge on Section 3(d) grounds. Post-grant challenges require strong evidence, including expert affidavits from pharmacologists or clinicians demonstrating that the patented form does not show enhanced therapeutic efficacy over the prior art substance.
Regulatory-patent interface: Coordinate patent strategy with regulatory approvals. DCGI (now CDSCO) approvals are based on safety and efficacy data. If the regulatory file shows bioequivalence with the known substance (i.e., no enhanced efficacy), this regulatory submission can be used as evidence against the patent in Section 3(d) proceedings. Conversely, if the regulatory file demonstrates superior efficacy, the patent applicant can use it to support the Section 3(d) threshold.
Key subsequent developments
- Bayer Corp. v. Natco Pharma (2012): India's first compulsory licence under Section 84, for sorafenib (kidney/liver cancer drug). The Intellectual Property Appellate Board upheld the licence.
- F. Hoffmann-La Roche v. Cipla (2015): Addressed patent infringement injunction standards in pharmaceutical cases — balance of convenience analysis considering public health impact.
- Lee Pharma v. AstraZeneca (2017): Applied Section 3(d) to reject a patent application for a diabetes drug combination, reinforcing the Novartis standard.
- Ferid Allani v. Union of India (2019): Clarified that Section 3(k) (computer program exclusion) should be interpreted narrowly, distinguishing software from pharmaceutical Section 3(d) analysis.
- India Patent Office Guidelines (2019-2024): Updated to incorporate Novartis standards for examining Section 3(d) objections, including specific evidence requirements.
Frequently asked questions
What type of evidence satisfies the "significantly enhanced therapeutic efficacy" standard?
The strongest evidence is comparative clinical trial data (Phase II or Phase III) showing that the new form produces superior therapeutic outcomes — higher cure rates, fewer adverse effects, lower dosage requirements, or improved patient compliance leading to better treatment adherence. In the absence of clinical data, well-designed comparative in vivo pharmacological studies demonstrating enhanced therapeutic effect may suffice. In vitro dissolution data or bioavailability studies alone are insufficient unless accompanied by evidence linking the improved bioavailability to enhanced therapeutic outcomes. Expert declarations and published scientific literature supporting the therapeutic superiority claim strengthen the application.
Can a new dosage form or formulation overcome Section 3(d)?
A new dosage form (e.g., sustained release, transdermal patch, nanoparticle formulation) faces the same Section 3(d) scrutiny if it uses a known substance. The applicant must demonstrate that the new formulation produces significantly enhanced therapeutic efficacy — not just convenient administration. However, if the formulation enables a genuinely new therapeutic outcome (e.g., a targeted delivery system that reaches tumour cells more effectively and demonstrates superior clinical outcomes), it may satisfy Section 3(d). The key is always clinical evidence of therapeutic superiority.
How does Section 3(d) interact with data exclusivity and regulatory protection?
India does not currently grant data exclusivity — generic manufacturers can reference the innovator's regulatory data for their own applications. This means Section 3(d) and the absence of data exclusivity work together to facilitate generic entry. Even if an innovator obtains a patent that survives Section 3(d) scrutiny, generic manufacturers can file abbreviated new drug applications using the innovator's data (once the patent expires or a compulsory licence is granted) without repeating clinical trials.
Can Novartis be distinguished for non-pharmaceutical patents?
Yes, but with limitations. The Court's interpretation of "efficacy" as "therapeutic efficacy" is specific to pharmaceutical substances. For non-pharmaceutical substances (chemicals, materials, agricultural products), "efficacy" under Section 3(d) would be interpreted in the context of the relevant industry — for example, "agricultural efficacy" for agrochemicals or "catalytic efficiency" for industrial chemicals. The broader principle — that new forms of known substances must show enhanced efficacy of the relevant kind — applies across all fields, but the specific therapeutic efficacy standard is limited to pharmaceuticals.
What is the current position on combination patents and Section 3(d)?
Combination patents (combining two known drugs into a single formulation) face significant Section 3(d) challenges. The combination must demonstrate synergistic therapeutic efficacy — the combined effect must be greater than the sum of the individual effects. Merely combining two known drugs for convenience (reducing pill burden) without demonstrating synergistic therapeutic benefit is likely to fail Section 3(d). Practitioners should prepare synergy studies showing that the combination produces therapeutic outcomes that neither drug achieves alone.